IPN01195

DRUG2 trials

Sponsors

Ipsen Pharma, Ipsen

Conditions

Advanced Solid TumorAdvanced Solid Tumour

Phase 1

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

RecruitingNCT06833008

IpsenAdvanced Solid Tumor

Start: 2025-03-14End: 2028-10-03Target: 85Updated: 2026-09-01

An open-label, phase I/II first-in-human, dose escalation and confirmation study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and anti-tumour activity of IPN01195 as single agent in adult participants with advanced solid tumours

RecruitingCTIS2024-519184-18-00

Ipsen PharmaAdvanced Solid Tumour

Start: 2025-05-30Target: 26Updated: 2025-11-03